The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic
shift since the dawn of the current century. This has been driven largely by the introduction of …

Simple Summary Bispecific antibodies (BsAbs) provide a new mode of targeting multiple
myeloma (MM) plasma cells (PCs), basing their action on the activation and redirection of …

Recent advancements in multiple myeloma (MM) treatment—including immunomodulatory
drugs, proteasome inhibitors, monoclonal antibodies, and T cell–redirecting therapies like …

Introduction Modern immunotherapy approaches are revolutionizing the treatment scenario
of relapsed/refractory (RR) multiple myeloma (MM) patients, providing an opportunity to …

Patients with multiple myeloma who present with refractory disease or relapse after
receiving the main classes of available drugs–immunomodulators, proteasome inhibitors …

Los pacientes con mieloma múltiple que presentan una enfermedad refractaria o en recaída
tras recibir las principales clases de fármacos disponibles—inmunomoduladores …

Every year, more than 150,000 cases of multiple myeloma (MM) are diagnosed worldwide,
and over 100,000 deaths caused by this malignancy are recorded. MM incidence is …

T-Cell Engagers Emerge Across Cancer Settings NEWS All NewsFDA BriefsOncology IconsSpecial
ReportsVoices from the Field CONFERENCES Conference CoverageConference ListingData …

Using the bispecific antibody REGN5459 in multiple myeloma resulted in durable, deep, and
dose-dependent responses in patients with relapsed/refractory multiple myeloma, according …

Bispecific antibody constructs represent an innovative immunotherapy approach that helps
the body's immune system target cancer cells and appears very promising for the treatment …